Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Solid Tumors

Recruiting

1/2

Start Date 06/09/2022

Age of Trial (yrs) 2.8

Gleevec-resistant

PRMT5 Inhibitor

Selective inhibitor of PRMT5

GIST not specified. GIST patient enrollment unknown.

CA240-0007 1719-001

Mirati Therapeutics Inc.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com Phone Number: 855-907-3286 Email: Clinical.Trials@bms.com First line of the email MUST contain the NCT# and Site #.

Oral

Study Overview

Brief Summary

This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Detailed Description

This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available to recommend Phase 2 regimens. In Phase 2, separate cohorts of patients by histological diagnosis and/or baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1719.

Eligibility Criteria

Description

Inclusion Criteria

Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue or ctDNA.
Unresectable or metastatic disease.
Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
Age ≥ 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.


Exclusion Criteria

Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
Active brain metastases or carcinomatous meningitis.
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
Major surgery within 4 weeks of first dose of study treatment.
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
Cardiac abnormalities.
Other protocol-defined Inclusion/Exclusion criteria apply.